Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | More
 
or
Watchlist | Portfolio
Site News
Contact
Market:

Qwest Corp (CTX)

Qwest Corp (CTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Captor Therapeutics Nominates the Molecular Glue CPT-6281 as Drug Candidate to Enter CTA/IND-Enabling Studies for the Treatment of Hepatocellular Carcinoma Globe Newswire - Wed Aug 10, 2022

WROCŁAW, Poland, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company dedicated to the development of...

CTX : 25.26 (+8.27%)
Captor Therapeutics to Host R&D Day on May 18, 2022 Globe Newswire - Thu May 5, 2022

WROCŁAW, Poland, May 05, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of targeted...

CTX : 25.26 (+8.27%)
Captor Therapeutics announces molecular targets of CT-01 program developing TPD therapy for hepatocellular carcinoma Globe Newswire - Tue Apr 12, 2022

CT-01 compounds induce degradation of GSPT1, SALL4 and another as yet undisclosed neo-substrateThe unique degradation profile supports the strong...

CTX : 25.26 (+8.27%)
Captor Therapeutics Invited to TPD Panel at the 8th Annual LSX World Congress 2022 Globe Newswire - Mon Apr 11, 2022

WROCLAW, Poland, April 11, 2022 (GLOBE NEWSWIRE) -- Captor Therapeutics S.A. (WSE:CTX), a biopharmaceutical company focused on the development of...

CTX : 25.26 (+8.27%)
Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma Globe Newswire - Thu Jan 13, 2022

Data confirm strong anticancer activity of two lead compounds in CT-01 programResults support advancement of CT-01 compounds towards IND expected in late...

CTX : 25.26 (+8.27%)

Barchart Exclusives

Why Suitors Are Desperately Seeking Anglo American Stock Barchart - 22 minutes ago
Producers all want to increase copper output to take advantage of rising demand in EVs, grid infrastructure and data centers - but that bullishness isn’t translating into the huge investments needed to develop new mines. Thus, the start of a bidding war for Anglo American. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot